// App-Quantinova.ai

O03 : Efficacy and safety of ixekizumab at week 24 in biologic experienced patients with active psoriatic arthritis summary results

Researchers

Presenter

  • Helena Marzo-Ortega

Principal Investigators

  • Pierluigi Meroni

  • Eva Galindez-Agirregoikoa

  • Frank Behrens

  • Andrew J Bradley

  • Soyi Liu Leage

  • Miriam Garcia

  • Christophe Sapin

  • Ji Chen Ho

  • Arnaud Constantin

  • Stephen Hall

Medical Centers

  • NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK

  • IRCCS Istituto Auxologico Italiano and University of Milan, Milan, Italy

  • Servicio de Reumatología, University Hospital of Basurto, Bilbao, SPAIN

  • Division of Rheumatology and IME Fraunhofer Project Group Translational Medicine & Pharmacology, Johann Wolfgang Goethe-University, Frankfurt am Main, GERMANY

  • Lilly International, Eli Lilly and Company, Indianapolis, IN

  • Department of Dermatology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City, TAIWAN

  • Department of Rheumatology, Hospital Pierre-Paul Riquet, Tolouse, FRANCE

  • Department of Medicine, Monash University, Bath, AUSTRALIA

Locations

  • United Kingdom

  • Italy

  • Spain

  • Germany

  • United States

  • Taiwan

  • France

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

  • Musculoskeletal

Disease

  • Psoriatic arthritis

Biomarkers

  • N/A

Drug/Treatment

  • LY2439821

Outcome

  • N/A

Study Design

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • III

Study Id's

  • NCT02349295

Sponsors

  • Eli Lilly and Company

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved